Biocidium Biopharmaceuticals
The website at the provided URL displays a 'Site Currently Unavailable' notice. No accessible content was available to extract company details, capabilities, technologies, products, or contact information.
Industries
Nr. of Employees
small (1-50)
Biocidium Biopharmaceuticals
Products
BCM-0184
Gram-positive antibiotic drug candidate targeting methicillin resistant Staphylococcus aureus (MRSA) with oral and topical formulations.
BCM-0146
Gram-positive antibiotic drug candidate targeting vancomycin resistant Enterococcus faecalis (VRE) with oral and topical formulations.
BCM-0168
Gram-positive antibiotic drug candidate targeting multi-drug resistant Streptococcus pneumoniae with oral and topical formulations.
BCM-0242
Gram-negative antibiotic drug candidate targeting carbapenem-resistant enterobacteriaceae (CRE) with oral and topical formulations.
BCM-0316
Novel antibiotic in preclinical trials targeting multiple drug-resistant bacteria including CRE, VRSA, DRNG, MDPA, and DRS.
BCM-0241
Novel antibiotic in preclinical trials targeting VRE (vancomycin resistant Enterococcus).
BCM-0184
Gram-positive antibiotic drug candidate targeting methicillin resistant Staphylococcus aureus (MRSA) with oral and topical formulations.
BCM-0146
Gram-positive antibiotic drug candidate targeting vancomycin resistant Enterococcus faecalis (VRE) with oral and topical formulations.
BCM-0168
Gram-positive antibiotic drug candidate targeting multi-drug resistant Streptococcus pneumoniae with oral and topical formulations.
BCM-0242
Gram-negative antibiotic drug candidate targeting carbapenem-resistant enterobacteriaceae (CRE) with oral and topical formulations.
BCM-0316
Novel antibiotic in preclinical trials targeting multiple drug-resistant bacteria including CRE, VRSA, DRNG, MDPA, and DRS.
BCM-0241
Novel antibiotic in preclinical trials targeting VRE (vancomycin resistant Enterococcus).